Are you checking expiration dates from your existing supplier of GLPs?

August 21, 2025

Managing GLP medications such as semaglutide requires vigilance in checking expiration dates to ensure medication efficacy and safety. Given the complexities surrounding stability, supply chain, and regulatory standards, understanding how to verify and handle these medications is vital for healthcare providers and patients alike.

The Significance of Expiration Dates in GLP Medications

Why is it important to verify the expiration date of GLP medications like semaglutide?

Verifying the expiration date of GLP-1 medications, such as semaglutide, is crucial because it ensures the medication's full potency and safety. Manufacturers guarantee their effectiveness only until the labeled expiry. Once past this date, the drug may lose its ability to control blood sugar levels or aid weight loss effectively.

Chemical stability is also a concern. Over time, the active ingredients can degrade or change, potentially causing side effects or reduced efficacy. Drugs stored improperly, even before expiration, are at increased risk of contamination and diminished safety.

To maintain treatment quality, always check the packaging for the expiry date before use. Discard expired medications responsibly, following local disposal guidelines, to prevent any health risks. Proper storage conditions—such as refrigeration or protection from light—help uphold the medication's stability until its expiration date.

What are proper storage and handling methods to maximize the shelf life of GLP medications?

Proper storage is vital to extending the shelf life of GLP medications. Initially, unopened medications like Ozempic and Wegovy should be stored in the refrigerator at around 36°F to 46°F. Once opened, these can typically be kept at room temperature (up to 86°F) for a limited period—generally 56 days for Ozempic and 28 days for Wegovy.

Original packaging should be kept intact, away from direct sunlight, heat, and freezing temperatures. Ensuring the medication is stored in a safe place away from children is also essential. Injectable GLP drugs require controlled room temperature storage during use, and opened vials or pens should be refrigerated afterward.

Handling entails avoiding exposure to elements that could degrade the medication, such as excessive heat or direct sunlight. Follow manufacturer instructions precisely. Educate patients on these storage practices to ensure medication effectiveness and safety.

How do manufacturers determine the expiration date of GLP medications?

Manufacturers establish expiration dates through rigorous stability testing. These tests involve assessing how the drug’s strength, purity, and overall quality change over time under specified storage conditions.

Typically, both real-time and accelerated stability studies are conducted across various batches. Data from these studies helps determine how long the medication maintains its integrity, leading to the official expiration date.

Regulatory bodies like the FDA review this stability data. If the data confirms the medication remains stable beyond the initial date, manufacturers can apply for an extension. This process ensures that the expiration date accurately reflects the drug’s safety and efficacy during its shelf life.

Is there a difference between FDA-approved and compounded GLP-1 products regarding safety and expiration?

Yes, substantial differences exist. FDA-approved GLP-1 drugs such as Ozempic and Wegovy have undergone extensive testing and regulatory review. They come with established expiration dates based on robust stability data, guaranteeing consistent quality and safety.

Conversely, compounded GLP-1 medications are prepared outside of FDA oversight by pharmacies. These products often use unverified ingredients, lack standardized testing, and do not have officially approved expiration dates. The safety, potency, and shelf life of compounded drugs are therefore uncertain.

Adverse events linked to compounded versions have been reported, including dosing errors and contamination, raising safety concerns. For reliable treatment, FDA-approved medications are the preferred choice given their validated safety profiles and known shelf life.

Are there regulatory guidelines regarding the checking and management of expiration dates for drugs like GLP-1?

Regulatory agencies such as the FDA have strict guidelines for managing drug expiration dates. They require drug manufacturers to perform stability testing under controlled conditions to determine how long a drug remains safe and effective.

Protocols include real-time and accelerated stability studies, with stability data supporting the expiration date. These processes ensure labeling accurately reflects the safe usage period.

For healthcare providers and pharmacists, regulations mandate regular checks of storage conditions and expiration dates. Proper inventory management, including First Expired, First Out (FEFO), minimizes wastage and prevents dispensing expired medication to patients.

How does the regulatory environment affect the management of expiration dates and supply chain issues for GLP medications?

The regulatory environment plays a vital role in controlling supply and ensuring medication quality. It requires clear documentation and monitoring through systems like the Drug Supply Chain Security Act (DSCSA), which uses serialization and verification protocols.

During shortages, regulatory agencies may approve shelf-life extensions or support stability testing to extend drug availability. For example, the FDA’s Shelf-Life Extension Program (SLEP) has tested and extended expiration dates for certain drugs stored in federal stockpiles.

However, in countries with weaker regulations, poor inventory management and lack of oversight can lead to increased wastage and expired supplies. Effective regulation, consistent monitoring, and adherence to guidelines help maintain supply, minimize waste, and ensure safe medication use.

What are the risks of using expired GLP medications?

Using expired GLP medications is risky due to potential loss of potency and safety. The active ingredients can degrade, rendering the medication less effective or ineffective. This can significantly impair treatment outcomes, especially for critical conditions like diabetes.

Beyond reduced efficacy, expired drugs may develop bacterial or fungal growth, especially in liquid formulations, increasing infection risks. Chemical changes may also cause unforeseen side effects or toxicity.

In some cases, the degradation products could cause allergic reactions or other adverse events. To mitigate these risks, always verify the expiration date before use, store medications properly, and discard any expired or suspect drugs.

What is the process for disposing of expired GLP medications safely?

Safe disposal involves following specific guidelines to prevent environmental contamination and misuse. Medications on the FDA’s Flush List, such as certain opioids, should be flushed down the toilet at authorized disposal sites.

For most medications, including GLP formulas, the preferred method is to use authorized drug take-back programs. These are available at pharmacies, law enforcement agencies, or community disposal events, allowing safe and environmentally friendly disposal.

If such programs are unavailable, medications can be mixed with undesirable substances like coffee grounds or dirt, sealed in a plastic bag, and discarded in household trash. Personal information on packaging should be removed to prevent misuse.

Always adhere to local regulations for medication disposal and consult healthcare professionals or local authorities for guidance.

Does semaglutide expire after a certain period, such as 28 days, once opened or reconstituted?

Yes, once opened or reconstituted, semaglutide—whether Ozempic or Wegovy—should be used within a specified period, usually 28 days when stored in the refrigerator at 36-46°F. This guideline ensures the medication remains stable and safe.

Extended use beyond this period risks bacterial contamination and degradation of active ingredients, reducing effectiveness and safety.

Proper storage during this period is essential. If the medication appears discolored, cloudy, or contains particles, it should be discarded.

Always follow manufacturer instructions and consult your healthcare provider for guidance on storage and disposal to maintain treatment safety.

The Impact of Supply Chain Disruptions on Medication Safety and Availability

How does the regulatory environment affect the management of expiration dates and supply chain issues for GLP medications?

Regulations play a crucial role in maintaining medication safety and ensuring that supplies are available when needed. Agencies like the FDA require manufacturers to perform stability testing, which establishes the expiration date based on how long the active ingredients remain stable when stored correctly. This process helps prevent medications from being used past their safe and effective period.

In the United States, the Drug Supply Chain Security Act (DSCSA) mandates detailed serialization and traceability measures. These regulations ensure that each medication unit can be tracked from production to patient, helping identify when products reach their expiration or show signs of degradation.

In contrast, in developing countries such as Ethiopia and Uganda, weak regulatory systems often lead to higher rates of drug expiration and wastage. Poor inventory management, lack of clear policies, and insufficient enforcement can result in expired drugs remaining in circulation, potentially causing harm.

Effective regulation encourages best practices like FIFO (First-In, First-Out) or FEFO (First-Expire, First-Out) inventory policies. These practices help healthcare providers prioritize stock with the earliest expiration dates, reducing waste.

When regulations are strong and well enforced, they support proper storage, handling, and disposal procedures. This reduces the risks associated with expired or compromised medications and promotes the availability of safe, effective treatments. Overall, a robust regulatory environment enhances supply chain monitoring, minimizes financial losses, and safeguards public health.

The Essential Role of Vigilance in GLP Medication Management

Properly checking expiration dates, adhering to storage guidelines, and understanding regulatory requirements are vital steps in maintaining the integrity, safety, and effectiveness of GLP medications. As supply chains become more complex and the availability of these drugs fluctuates, healthcare providers and patients must stay informed and proactive to prevent the use of expired or compromised medications. Such vigilance not only ensures optimal treatment outcomes but also upholds the highest standards of drug safety and regulatory compliance, safeguarding patient health now and in the future.

References

Myasthenia Gravis and IVIG: What Patients Need to Know About IV Therapy
July 20, 2026
Learn how IVIG therapy works for myasthenia gravis, when it's used, what to expect during infusions, how home IVIG is coordinated, and how Pharmko supports MG patients and their neurologists.
Dobutamine and Inotrope Therapy at Home
July 17, 2026
Learn how home dobutamine infusion works for advanced heart failure, who qualifies, how continuous inotrope therapy is managed at home, and how Pharmko supports cardiac patients and heart failure teams.
CIDP and Home Infusion: IVIG Treatment, Dosing Schedule, and Long-Term Management
July 16, 2026
Learn how IVIG therapy works for CIDP, what the dosing schedule looks like, how to transition to home infusion, and how Pharmko supports long-term CIDP management across 22+ states.
Compounded IV Medications
July 15, 2026
Most medications that patients receive at a hospital or pharmacy come in standardized, commercially manufactured forms, a 500mg antibiotic vial, a pre-filled syringe, a fixed-concentration IV bag. These products work well for many patients. But a significant portion of patients receiving IV therapy have clinical needs that commercial products cannot meet: a dose the manufacturer doesn't make, a formulation incompatible with the patient's allergy profile, or a combination of nutrients that must be tailored to individual lab values. For these patients, compounded IV medications are not optional, they are clinically necessary. Pharmko's sterile compounding services prepare customized IV medications for patients across 22+ states, with every formulation reviewed by a licensed pharmacist and prepared in a USP <797> compliant cleanroom. What Makes an IV Medication 'Compounded'? A compounded medication is one that is prepared specifically for an individual patient by a licensed pharmacist, rather than manufactured in bulk by a pharmaceutical company. Compounding involves combining, mixing, or altering ingredients, active pharmaceutical ingredients, diluents, preservatives, to create a final preparation that meets the patient's unique prescription requirements. For IV therapy specifically, compounding means preparing a sterile preparation, one that is completely free of viable microorganisms and safe to inject or infuse directly into the bloodstream. This requires specialized facilities, equipment, training, and quality systems that go far beyond what a standard retail pharmacy can provide. Pharmko is exclusively a sterile compounding pharmacy. We do not compound oral medications, topical creams, or non-sterile preparations. Every product we make is intended for intravenous, intraperitoneal, or subcutaneous administration. When Are Compounded IV Medications Necessary? The required dose doesn't exist commercially Pharmaceutical manufacturers produce medications in standardized strengths and volumes based on average patient needs. Pediatric patients, patients with renal or hepatic impairment requiring dose adjustments, or patients whose weight or clinical status falls outside standard ranges may need concentrations or volumes that no commercial product provides. Compounding fills this gap precisely. The patient has an allergy to a commercial formulation's inactive ingredients Commercial IV products often contain preservatives, stabilizers, or diluents, sulfites, benzyl alcohol, certain dyes, that some patients cannot tolerate. A compounding pharmacy can prepare an equivalent formulation without the offending ingredient, allowing the patient to receive the therapy safely. The medication requires individualized nutrient formulation Total parenteral nutrition (TPN) is the clearest example: every TPN formula must be individually compounded because no commercial product can provide the precise combination of amino acids, dextrose, lipids, electrolytes, vitamins, and trace minerals a specific patient needs. The formula changes as the patient's labs, weight, and clinical status change, making standardization impossible. The commercial product is unavailable or in shortage Drug shortages are a persistent reality in the US pharmaceutical supply chain. When a commercially manufactured IV medication becomes unavailable, compounding pharmacies can often prepare an equivalent formulation from available active pharmaceutical ingredients, bridging the gap and maintaining continuity of therapy for patients who cannot wait. The therapy requires a custom delivery format Some IV medications require specific pH, osmolarity, or concentration adjustments for compatibility with a patient's IV access device or concurrent medications. A compounding pharmacist reviews compatibility and prepares formulations that are safe and stable for the specific administration route and equipment the patient is using. How Compounded IV Medications Are Made Step 1: Prescription review Every compounded IV medication begins with a valid prescription from a licensed prescriber. Pharmko's pharmacists review the prescription for clinical appropriateness, dosing accuracy, ingredient compatibility, and stability before compounding begins. Step 2: Ingredient sourcing and verification Active pharmaceutical ingredients for compounding must come from FDA-registered suppliers and meet USP monograph specifications. Each lot is verified for identity, potency, and purity before use. Step 3: Sterile preparation in a controlled environment Preparation occurs in an ISO Class 5 laminar airflow workbench or biological safety cabinet, located within a buffer room that meets ISO Class 7 air quality standards. Pharmacy technicians follow validated, written procedures for each preparation type, using aseptic technique to prevent contamination at every step. Step 4: Pharmacist verification and release A licensed pharmacist performs a final check of every preparation, verifying appearance, volume, labeling, and documentation, before the product is released. High-risk or complex preparations may undergo sterility testing with defined beyond-use dates based on test results. Step 5: Cold-chain delivery Most compounded IV medications require refrigeration. Pharmko uses validated cold-chain packaging and delivery logistics to ensure products arrive within their stability windows and remain temperature-controlled until the patient uses them. Quality Standards That Matter Not all compounding pharmacies operate at the same standard. The relevant quality benchmarks for sterile compounding are: USP <797> compliance, the national standard for sterile compounding environments, personnel, and processes. Our guide on USP <797> and USP <800> explains what compliance means in practice ACHC accreditation, independent third-party verification that Pharmko meets clinical quality standards for home infusion and sterile compounding State pharmacy board licensure, Pharmko is licensed in every state where we serve patients Environmental and personnel monitoring, documented air and surface sampling, personnel gowning competency assessments, and media fill testing at defined intervals For a foundational overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . → Contact Pharmko about compounded IV medications: 1-877-540-2003
home infusion therapy Pennsylvania
July 14, 2026
Pharmko provides home infusion therapy across Pennsylvania, IV antibiotics, IVIG, TPN, biologics, and specialty medications. Licensed, ACHC accredited, and available 24/7 statewide.
Home Infusion Therapy in New Jersey
July 14, 2026
Pharmko provides home infusion therapy across New Jersey, IV antibiotics, IVIG, TPN, IDPN, biologics, and more. Licensed, ACHC accredited, and available 24/7 statewide.
Renal dietitian reviewing albumin labs for a peritoneal dialysis patient
July 10, 2026
When to consider IPN for peritoneal dialysis patients with low albumin: clinical criteria, the stepwise nutrition approach, and the referral process.
Nephrologist reviewing dialysis nutrition options for an ESRD patient
July 10, 2026
IPN vs. IDPN explained: how each parenteral nutrition therapy works, who qualifies, and how to choose the right option for ESRD dialysis patients.
How Home Infusion Reduces Hospital Readmissions
July 10, 2026
Home infusion therapy is associated with lower hospital readmission rates, fewer complications, and significant cost savings. Review the clinical evidence and learn how Pharmko supports discharge planning teams.
Primary Immune Deficiency and IVIG: A Guide for Newly Diagnosed Patients
July 8, 2026
Newly diagnosed with primary immune deficiency? Learn how IVIG therapy works, what to expect from your first infusions, how home IVIG is coordinated, and how Pharmko supports PID patients long-term.
Show More